Scarica l'app Stockscreener
35.28
2.11%
0.73
Dopo l'orario di chiusura:
35.28
Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie
Kymera Therapeutics Inc’s results are impressive - uspostnews.com
Market Momentum Report: Kymera Therapeutics Inc (KYMR)’s Positive Close at 34.55 - DWinneX
Invesco Ltd. Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Wells Fargo & Company MN Acquires 7,487 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Closing Figures Unveiled: Kymera Therapeutics Inc (KYMR) Drop -7.60, Closes at 27.37 - DWinneX
JPMorgan Chase & Co. Lowers Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Why Kymera Therapeutics (KYMR) Stock is Moving Today - GuruFocus
Why Kymera Therapeutics Stock Crushed it This Week - Yahoo Finance
Kymera Therapeutics Inc (KYMR) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Kymera Therapeutics Inc [KYMR] Shares Rise 9.32 % on Thursday - knoxdaily.com
KYMR’s Stock Market Adventure: -16.58% YTD Growth Amidst Volatility - investchronicle.com
Daily Market Movement: Kymera Therapeutics Inc (KYMR) Sees a 9.32 Increase, Closing at 33.56 - DWinneX
Kymera Therapeutics (KYMR) to Reveal New Candidate and Q1 2025 F - GuruFocus
Kymera Therapeutics (KYMR) to Reveal New Candidate and Q1 2025 Financials | KYMR Stock News - GuruFocus
Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025 - The Manila Times
Kymera Unveils Revolutionary Oral Drug Program Targeting Untapped Autoimmune Disease Pathway - Stock Titan
Is Kymera Therapeutics Inc (KYMR) worth investing in despite its overvalued state? - uspostnews.com
Kymera Therapeutics (KYMR) Begins Phase 1b Trial for Atopic Dermatitis Treatment | KYMR Stock News - GuruFocus
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader - The Manila Times
Breakthrough Oral Treatment for Eczema: First Patient Receives New STAT6 Degrader Drug in Clinical Trial - Stock Titan
Kymera Therapeutics Inc (KYMR) Stock: A Year of Declines and Increases - investchronicle.com
Learn to Evaluate (KYMR) using the Charts - news.stocktradersdaily.com
Investor’s Delight: Kymera Therapeutics Inc (KYMR) Closes Strong at 33.27, Up 0.76 - DWinneX
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $56.36 Consensus Target Price from Analysts - Defense World
Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last? - MSN
Kymera Therapeutics Appoints Noah Goodman as Chief Business Offi - GuruFocus
Kymera Therapeutics appoints new Chief Business Officer - Investing.com Australia
Kymera Therapeutics appoints new Chief Business Officer By Investing.com - Investing.com South Africa
Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer - citybiz
Strategic Power Move: Kymera Lands M&A Expert to Accelerate Drug Development Deals - Stock Titan
Kymera stock touches 52-week low at $20.77 amid market challenges - Investing.com Australia
Kymera stock touches 52-week low at $20.77 amid market challenges By Investing.com - Investing.com South Africa
Vanguard Group Inc. Raises Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
KLP Kapitalforvaltning AS Makes New Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
(KYMR) Trading Report - news.stocktradersdaily.com
Teacher Retirement System of Texas Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera stock touches 52-week low at $28.75 amid market challenges - Investing.com Australia
Kymera Therapeutics identifies new STAT6 degraders - BioWorld MedTech
Swiss National Bank Buys 10,300 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera at H.C. Wainwright Conference: Strategic Moves in Immunology By Investing.com - Investing.com Canada
Victory Capital Management Inc. Raises Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Charles Schwab Investment Management Inc. Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Analyzing Big Cypress Acquisition (OTCMKTS:BCYP) and Kymera Therapeutics (NASDAQ:KYMR) - Defense World
Bank of New York Mellon Corp Has $5.11 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Bank of New York Mellon Corp Has $5.11 Million Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - The AM Reporter
Citigroup Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - Defense World
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Citigroup Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendation - Nasdaq
Citigroup starts coverage of Kymera with $52 PT - TradingView
(KYMR) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Why Kymera Therapeutics’ Stock is Making Waves - TipRanks
Kymera at TD Cowen Conference: Focus on Clinical Advancements By Investing.com - Investing.com UK
Don't Ignore The Insider Selling In Kymera Therapeutics - Simply Wall St
Time To Worry? Analysts Just Downgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Outlook - Yahoo Finance
0.47%
2.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):